Additional information
by Jose Luis Pedraz Muñoz (Editor), Laura Saenz del Burgo Martínez (Editor), Gustavo Puras Ochoa (Editor)
The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D Printing and Bioprinting for Pharmaceutical and Medical Applications discusses emerging approaches related to these game-changer technologies in such areas as drug development, medical devices, and bioreactors.
Key Features:
- Offers an overview of applications, the market, and regulatory analysis
- Analyzes market research of 3D printing and bioprinting technologies
- Reviews 3D printing of novel pharmaceutical dosage forms for personalized therapies and for medical devices, as well as the benefits of 3D printing for training purposes
- Covers 3D bioprinting technology, including the design of polymers and decellularized matrices for bio-inks development, elaboration of 3D models for drug evaluation, and 3D bioprinting for musculoskeletal, cardiovascular, central nervous system, ocular, and skin applications
- Provides risk-benefit analysis of each application
- Highlights bioreactors, regulatory aspects, frontiers, and challenges
This book serves as an ideal reference for students, researchers, and professionals in materials science, bioengineering, the medical industry, and healthcare.
Author Biography
José Luis Pedraz is Professor and principal researcher in the NanoBioCel group at the University of the Basque Country (UPV/EHU). The research group belongs to the CIBER-BBN of the Carlos III Health Institute, where he serves as the head and director of the medicine formulation laboratory (ICTS) Nanbiosis. Dr. Pedraz is also founder and director of the Pharmaceutical Development Unit of the Basque Country, currently TECNALIA Pharma Labs integrated in the TECNALIA Corporation within a joint project with the UPV/EHU, of which he is scientific director. He had a PhD in Pharmacy from the University of Salamanca.
Gustavo Puras is Professor at University of the Basque Country (UPV/EHU), Department of Pharmacy and Food Sciences. He is a member of the NanoBioCel research group at UPV/EHU and the National System of Researchers of Mexico (SNI). He is Professor in the Master's Program of Pharmacology, Development, Evaluation and Rational Use of Medicines at UPV/EHU. He received a PhD in Pharmacy from UPV/EHU.
Laura Saenz del Burgo is Professor at the University School of Nursing in Vitoria-Gasteiz and Associate Professor at University of the Basque Country (UPV/EHU) in the Department of Pharmacy and Food Sciences. She is a member of the NanoBioCel research group at UPV/EHU and part of the CIBER-BBN and gives technical assistance to the Nanbiosis platform (Drug Formulation). She received the PhD in Pharmacy from UPV/EHU and has worked as a postdoctoral researcher at the Institute of Molecular, Cell and Systems Biology, University of Glasgow.
Jon Zarate is Associate Professor, Department of Pharmacy and Food Sciences, Professor of the Doctoral Program in Drug Research and Evaluation, Application of Pharmaceutical Technology to the Development of Advanced Therapies, and Professor in the Master's Program in Pharmacology, Development, Evaluation and Rational Use of Medicines at University of the Basque Country (UPV/EHU). He is a member of the NanoBioCel research group at the same institution. He received a PhD in Pharmacy from UPV/EHU.
